Cover Image
QR Code

When to Consider Immune Checkpoint Inhibitors in Oncogene-Driven Non-Small Cell Lung Cancer?

Opinion Statement: Targeted therapies and more recently immune checkpoint inhibitors (ICI) have transformed the treatment landscape of advanced NSCLC. Clinical trials investigating immune checkpoint inhibitors (ICI) have usually excluded patients with oncogenic drivers, so that the outcome of these...

Full description

Published in:Current Treatment Options in Oncology Vol. 20; no. 7
Main Authors: Mhanna, Laurent, Guibert, Nicolas, Milia, Julie, Mazieres, Julien
Format: research Journal Article
Published: Springer Nature Jul2019
Online Access:View this record in EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=137275540&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 137275540
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        15272729
        3KHC
      jtl: Current Treatment Options in Oncology
      issn: 15272729
      maglogo: N
    pubinfo:
      dt: Jul2019
      vid: 20
      iid: 7
      pid: 237
      pub: Springer Nature
      place: New York, New York
    artinfo:
      ui:
        137275540
        137275540
        NLM31172347
        137275540
        10.1007/s11864-019-0652-3
        NLM31172347
        137275540
      ppct: 1
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: When to Consider Immune Checkpoint Inhibitors in Oncogene-Driven Non-Small Cell Lung Cancer?
      aug:
        au:
          Mhanna, Laurent
          Guibert, Nicolas
          Milia, Julie
          Mazieres, Julien
        affil: Pulmonology Department, Toulouse University Hospital, Université Paul Sabatier, Toulouse, France
      sug:
        subj:
          Carcinoma, Non-Small-Cell Lung Drug Therapy
          Lung Neoplasms Drug Therapy
          Antineoplastic Agents Therapeutic Use
          Carcinoma, Non-Small-Cell Lung
          Lung Neoplasms Pathology
          Protein Kinase Inhibitors Therapeutic Use
          Lung Neoplasms Immunology
          Carcinoma, Non-Small-Cell Lung Pathology
          Lung Neoplasms
          Drug Therapy Methods
          Oncogenes
          Human
          Carcinoma, Non-Small-Cell Lung Immunology
          Clinical Trials
          Clinical Assessment Tools
          Scales
      ab: Opinion Statement: Targeted therapies and more recently immune checkpoint inhibitors (ICI) have transformed the treatment landscape of advanced NSCLC. Clinical trials investigating immune checkpoint inhibitors (ICI) have usually excluded patients with oncogenic drivers, so that the outcome of these agents in this population is poorly known. In patients with oncogenic addiction, targeted therapy remains clearly the best option, and the place of immunotherapy in this population has not been clearly defined yet.Based on available data, we suggest that (i) immunotherapy single agent should be proposed only after exhaustion of more validated treatments, (ii) combinations of immunotherapy with targeted therapies are of interest provided that we can manage toxicity and find the best sequence, (iii) a combination of immunotherapy with chemotherapy may be appealing in patients pretreated with targeted agents. The best way to opt in for the best strategy will depend upon the identification of adequate biomarkers. New basic and clinical research is awaited in this field.
      pubtype: Academic Journal
      doctype:
        research
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N